Novartis, Drug Prices & Medicare Spending

Novartis manufactures 27 drugs tracked by Medicare Part D with total spending of $19.9B.

Drugs Tracked

$19.9B

Medicare Spending

$488.16

Avg Cost/Claim

93%

Have Generics

Novartis Drugs, Ranked by Medicare Spending

#	Drug	Generic Name	Cost/Claim	Medicare Spending	YoY Change	Generic?
1	Entresto	Sacubitril/Valsartan	$379.00	$4.8B	+18.3%	No
2	Cosentyx	Secukinumab	$3,616.00	$3.1B	+8.9%	Yes
3	Kisqali	Ribociclib	$7,621.00	$1.9B	+28.5%	Yes
4	Kesimpta	Ofatumumab	$8,425.00	$1.6B	+68.4%	Yes
5	Gilenya	Fingolimod	$5,738.00	$1.4B	-14.8%	No
6	Tasigna	Nilotinib	$7,806.00	$765.0M	-8.2%	Yes
7	Tafinlar	Dabrafenib	$12,577.00	$654.0M	+6.2%	Yes
8	Mekinist	Trametinib	$11,813.00	$567.0M	+4.6%	Yes
9	Afinitor	Everolimus	$11,813.00	$567.0M	-14.3%	Yes
10	Mayzent	Siponimod	$6,593.00	$567.0M	+14.2%	Yes
11	Xiidra	Lifitegrast	$229.00	$567.0M	+4.8%	Yes
12	Gleevec	Imatinib	$5,302.00	$456.0M	-32.1%	Yes
13	Leqvio	Inclisiran	$1,391.00	$345.0M	+186.4%	Yes
14	Focalin XR	Dexmethylphenidate XR	$139.00	$345.0M	-18.6%	Yes
15	Beovu	Brolucizumab	$1,391.00	$345.0M	+18.4%	Yes
16	Votrient	Pazopanib	$8,214.00	$345.0M	-12.4%	Yes
17	Stalevo	Carbidopa/Levodopa/Entacapone	$189.00	$234.0M	-8.4%	Yes
18	Exelon	Rivastigmine (patch)	$189.00	$234.0M	-18.4%	Yes
19	Zortress	Everolimus (transplant)	$718.00	$178.0M	+4.2%	Yes
20	Clozapine	Clozapine	$96.00	$178.0M	-8.4%	Yes
21	Diclofenac	Diclofenac Sodium	$14.00	$123.0M	-18.6%	Yes
22	Rivastigmine	Rivastigmine Tartrate	$50.00	$123.0M	-18.6%	Yes
23	Tabrecta	Capmatinib	$15,375.00	$123.0M	+32.4%	Yes
24	Comtan	Entacapone	$197.00	$123.0M	-14.2%	Yes
25	Oxcarbazepine	Oxcarbazepine	$48.00	$89.0M	-22.6%	Yes
26	Carbamazepine	Carbamazepine	$36.00	$89.0M	-14.6%	Yes
27	Tykerb	Lapatinib	$7,417.00	$89.0M	-22.4%	Yes

Frequently Asked Questions

Novartis manufactures 27 drugs tracked by Medicare Part D, with total annual spending of $19.9B.

Tabrecta (Capmatinib) is the most expensive at $15,375.00 per claim.

25 of 27 Novartis drugs (93%) have generic alternatives available. Generic drugs can save patients 30-80% compared to brand-name versions.

The this entity record above pulls directly from CMS Medicare Part D Drug Spending data. What follows is the per-entity context — how this entity sits in the broader U.S. Medicare prescription-drug pricing distribution and which underlying factors drive the headline numbers.

The methodology behind every numeric value on this page is publicly documented on the CMS Medicare Part D Drug Spending data portal and described in detail on this site’s methodology page. Refresh cadence varies by underlying series; the page surfaces the as-of date for each number so readers can trace any figure back to the source release.

For readers using this page as a decision input, the related-entity pages elsewhere on the site provide the comparison set. The most useful comparison for this entity is typically a peer within U.S. prescription drugs with similar size, similar exposure, or similar geography — not the national-level summary alone.

Source: CMS Medicare Part D Spending, 2026.